Diagnóstico Molecular en Microbiología Clínica
CTS220
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas
Madrid, EspañaPublications in collaboration with researchers from Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (9)
2024
-
Antibiotic use and outcome in patients with negative blood cultures, a new target population for antimicrobial stewardship interventions: A prospective multicentre cohort (NO-BACT)
Journal of Infection, Vol. 88, Núm. 2, pp. 95-102
-
Whole-genome characterisation of Escherichia coli isolates from patients with bacteraemia presenting with sepsis or septic shock in Spain: a multicentre cross-sectional study
The Lancet Microbe, Vol. 5, Núm. 4, pp. e390-e399
2023
-
Conventional Hospitalization versus Sequential Outpatient Parenteral Antibiotic Therapy for Staphylococcus aureus Bacteremia: Post-Hoc Analysis of a Multicenter Observational Cohort
Antibiotics, Vol. 12, Núm. 1
-
Detection of High Level of Co-Infection and the Emergence of Novel SARS CoV-2 Delta-Omicron and Omicron-Omicron Recombinants in the Epidemiological Surveillance of Andalusia
International journal of molecular sciences, Vol. 24, Núm. 3
-
Effect of viral storm in patients admitted to intensive care units with severe COVID-19 in Spain: a multicentre, prospective, cohort study
The Lancet Microbe, Vol. 4, Núm. 6, pp. e431-e441
-
Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-year time lapse analysis
The Lancet Regional Health - Europe, Vol. 34
-
Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections
The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 5, pp. 1195-1200
-
The CARBA-MAP study: national mapping of carbapenemases in Spain (2014–2018)
Frontiers in Microbiology, Vol. 14
2022
-
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa
The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 10, pp. 2809-2815